Literature DB >> 9200448

xid affects events leading to B cell cycle entry.

K Brorson1, M Brunswick, S Ezhevsky, D G Wei, R Berg, D Scott, K E Stein.   

Abstract

X-linked agammaglobulinemia patients and X-linked immunodeficient (xid) mice possess mutations in the Bruton's tyrosine kinase (Btk kinase) gene and display defects in B cell development and activation by sIg cross-linking. Btk is an early activation kinase in sIg-cross-linked B cells. xid does not ablate Btk protein kinase activity, and immediate signal transduction events, such as tyrosine phosphorylation, occur in sIg-activated xid B cells. These cells do not subsequently progress into cell division and have a high rate of apoptosis, which has been shown to correlate with an absence of sIg-mediated induction of the bcl-xL protein. To establish the point where Btk activity is critical for progression beyond immediate signaling, we examined early and late events in sIg-cross-linked xid B cells. Induction of proto-oncogenes and nuclear factors occurred normally in xid cells. However, induction of cyclins and increased GAPDH mRNA was not observed in xid cells. Degradation of the cyclin inhibitor p27Kip1 occurred normally in xid cells. After 24 h of culture with anti-mu, the remaining live, nonapoptotic xid cells were enlarged, viable, and primed for subsequent stimulation by LPS. Our data suggest that the Btk kinase is not essential for several G1 events and that the failure of sIg-activated xid B cells to enter cell cycle correlates with a defect of cyclin induction. Moreover, these data suggest that Btk is important not only for immediate events following B cell activation and control of apoptosis but also for subsequent events leading to cyclin activation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9200448

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Cell cycle control mechanisms in B-1 and B-2 lymphoid subsets.

Authors:  Michael J Piatelli; Debra Tanguay; Thomas L Rothstein; Thomas C Chiles
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain.

Authors:  D C Shields; K E Schaecher; T C Saido; N L Banik
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

3.  Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.

Authors:  Dennis Dobrovolsky; Eric S Wang; Sara Morrow; Catharine Leahy; Tyler Faust; Radosław P Nowak; Katherine A Donovan; Guang Yang; Zhengnian Li; Eric S Fischer; Steven P Treon; David M Weinstock; Nathanael S Gray
Journal:  Blood       Date:  2018-12-13       Impact factor: 22.113

4.  Transgenic mice expressing dominant-negative bright exhibit defects in B1 B cells.

Authors:  Jamee C Nixon; Scott Ferrell; Cathrine Miner; Athenia L Oldham; Ute Hochgeschwender; Carol F Webb
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

5.  Early induction of cyclin D2 expression in phorbol ester-responsive B-1 lymphocytes.

Authors:  D A Tanguay; T P Colarusso; S Pavlovic; M Irigoyen; R G Howard; J Bartek; T C Chiles; T L Rothstein
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

6.  Independent and opposing roles for Btk and lyn in B and myeloid signaling pathways.

Authors:  A B Satterthwaite; C A Lowell; W N Khan; P Sideras; F W Alt; O N Witte
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

7.  Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation.

Authors:  U D Bajpai; K Zhang; M Teutsch; R Sen; H H Wortis
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

8.  B-1 cell development: evidence for an uncommitted immunoglobulin (Ig)M+ B cell precursor in B-1 cell differentiation.

Authors:  S H Clarke; L W Arnold
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

9.  Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement.

Authors:  J B Petro; S M Rahman; D W Ballard; W N Khan
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

Review 10.  Targeting Bruton's tyrosine kinase in B cell malignancies.

Authors:  Rudi W Hendriks; Saravanan Yuvaraj; Laurens P Kil
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.